Combined pre- and postoperative adjuvant radiation therapy for bladder cancer--a ten year experience

Int J Radiat Oncol Biol Phys. 1992;24(3):463-8. doi: 10.1016/0360-3016(92)91060-z.

Abstract

From 1978 through 1987, 78 patients with carcinoma of the bladder were treated with combined pre- and postoperative adjuvant radiation therapy. All were given a single dose of pre-operative radiation therapy, 500 cGy, either on the day of or the day before cystectomy. Histological staging on the cystectomy specimens according to the TNM classification system was performed. Forty patients with Stage P2 (high grade III and IV), P3A, P3B, P4A, or N+ underwent planned high dose postoperative radiation therapy (4000-4500 cGy) in 5 weeks. The whole pelvis was treated with conventional fractionation of 180 cGy 5 days per week. Median follow-up was 52 months, with 36 months minimum follow-up. There was a 67% overall 5-year survival, and those with P1 and P2 (Grade I and II) had an 84% 5-year survival. Survival for patients with P2 tumor (Grade III and IV), P3A, P3B, and P4/N+ stages was 57%, 56%, 39%, and 50%, respectively. Bowel obstructions developed in 8% of patients who received no postoperative radiation therapy and 37% in those who did. Genitourinary complication rates were similar in both groups, 13% in the group that received no postoperative radiation therapy and 10% in the group that did. Although the planned approach of combined pre- and postoperative radiation therapy for unfavorable stages of bladder cancer is associated with a better than 50% 5-year survival rate (except in Stage P3B cancer), the bowel toxicity was unacceptably high.

MeSH terms

  • Aged
  • Combined Modality Therapy
  • Cystectomy
  • Female
  • Humans
  • Male
  • Postoperative Care
  • Preoperative Care
  • Retrospective Studies
  • Survival Analysis
  • Survival Rate
  • Urinary Bladder Neoplasms / epidemiology
  • Urinary Bladder Neoplasms / radiotherapy*
  • Urinary Bladder Neoplasms / surgery